Allosteric compounds that stimulate Hsp90 adenosine triphosphatase (ATPase) activity were rationally designed, showing anticancer potencies in the low micromolar to nanomolar range. In parallel, the mode of action of these compounds was clarified and a quantitative model that links the dynamic ligand–protein cross-talk to observed cellular and in vitro activities was developed. The results support the potential of using dynamics-based approaches to develop original mechanism-based cancer therapeutics.
Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads / I. D'Annessa, S. Sattin, J. Tao, PENNATI MARZIA, C. Sànchez Martìn, E. Moroni, A. Rasola, N. Zaffaroni, D.A. Agard, BERNARDI ANNA, G. Colombo. - In: CHEMISTRY-A EUROPEAN JOURNAL. - ISSN 0947-6539. - 23:22(2017 Mar 22), pp. 5188-5192. [10.1002/chem.201700169]
Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads
S. SattinSecondo
;M. Pennati;A. BernardiPenultimo
;
2017
Abstract
Allosteric compounds that stimulate Hsp90 adenosine triphosphatase (ATPase) activity were rationally designed, showing anticancer potencies in the low micromolar to nanomolar range. In parallel, the mode of action of these compounds was clarified and a quantitative model that links the dynamic ligand–protein cross-talk to observed cellular and in vitro activities was developed. The results support the potential of using dynamics-based approaches to develop original mechanism-based cancer therapeutics.
| File | Dimensione | Formato | |
|---|---|---|---|
|
D'Annessa_et_al-2017-Chemistry_-_A_European_Journal.pdf
accesso riservato
Descrizione: articolo pubblicato
Tipologia:
Publisher's version/PDF
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
